MGAT2 and metabolic syndrome: Inactivation of MGAT2 by genetic manipulation and pharmacological intervention supports the idea that targeting the MAG pathway as a therapeutic for metabolic syndrome is a viable option for inhibiting intestinal TAG synthesis.